DBDonald. W. Bowden

Donald. W. Bowden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Donald. W. Bowden has a total of 237 co-authors. Here are the top co-authors by number of shared publications:

  • Carl D. Langefeld

    Department of Biostatistical Sciences - Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, North Carolina 27157

    30 shared publications
  • Barry I. Freedman

    Department of Internal Medicine, Nephrology Wake Forest School of Medicine Winston - Salem North Carolina

    21 shared publications
  • Nicholette D. Palmer

    Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC

    14 shared publications
  • Jill M. Norris

    Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, CO

    11 shared publications
  • John Jeffrey Carr

    Vanderbilt University Medical Center

    10 shared publications
  • Julie T. Ziegler

    Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC

    9 shared publications

Latest Publications

  • Open Access

    A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants

    by Andrew R. Wood, Anna Jonsson, Anne U. Jackson, Nan Wang, Nienke van Leewen, Nicholette D. Palmer, Sayuko Kobes, Joris Deelen, Lorena Boquete-Vilarino, Jussi Paananen, et al.

    Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed the largest genome-wide association study of first-phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 individuals without diabetes from 10 studies. We aimed to refine the mechanisms of 178 known associations between common variants and glycemic traits and identify new loci. Thirty type 2 diabetes or fasting glucose–raising alleles were associated with a measure of first-phase insulin secretion at P < 0.05 and provided new evidence, or the strongest evidence yet, that insulin secretion, intrinsic to the islet cells, is a key mechanism underlying the associations at the HNF1A, IGF2BP2, KCNQ1, HNF1B, VPS13C/C2CD4A, FAF1, PTPRD, AP3S2, KCNK16, MAEA, LPP, WFS1, and TMPRSS6 loci. The fasting glucose–raising allele near PDX1, a known key insulin transcription factor, was strongly associated with lower first-phase insulin secretion but has no evidence for an effect on type 2 diabetes risk. The diabetes risk allele at TCF7L2 was associated with a stronger effect on peak insulin response than on C-peptide–based insulin secretion rate, suggesting a possible additional role in hepatic insulin clearance or insulin processing. In summary, our study provides further insight into the mechanisms by which common genetic variation influences type 2 diabetes risk and glycemic traits.


  • Open Access

    Dopamine pathway gene variants may modulate cognitive performance in the DHS – Mind Study

    by Susan E. Martelle, Laura M. Raffield, Nichole D. Palmer, Amanda J. Cox, Barry I. Freedman, Christina E. Hugenschmidt, Jeff D. Williamson, Don W. Bowden

    Background: There is an established association between type 2 diabetes and accelerated cognitive decline. The exact mechanism linking type 2 diabetes and reduced cognitive function is less clear. The monoamine system, which is extensively involved in cognition, can be altered by type 2 diabetes status. Thus, this study hypothesized that sequence variants in genes linked to dopamine metabolism and associated pathways are associated with cognitive function as assessed by the Digit Symbol Substitution Task, the Modified Mini‐Mental State Examination, the Stroop Task, the Rey Auditory‐Verbal Learning Task, and the Controlled Oral Word Association Task for Phonemic and Semantic Fluency in the Diabetes Heart Study, a type 2 diabetes‐enriched familial cohort (n = 893).Methods: To determine the effects of candidate variants on cognitive performance, genetic association analyses were performed on the well‐documented variable number tandem repeat located in the 3' untranslated region of the dopamine transporter, as well as on single‐nucleotide polymorphisms covering genes in the dopaminergic pathway, the insulin signaling pathway, and the convergence of both. Next, polymorphisms in loci of interest with strong evidence for involvement in dopamine processing were extracted from genetic datasets available in a subset of the cohort (n = 572) derived from Affymetrix® Genome‐Wide Human SNP Array 5.0 and 1000 Genomes imputation from this array.Results: The candidate gene analysis revealed one variant from the DOPA decarboxylase gene, rs10499695, to be associated with poorer performance on a subset of Rey Auditory‐Verbal Learning Task measuring retroactive interference (P = 0.001, β = −0.45). Secondary analysis of genome‐wide and imputed data uncovered another DOPA decarboxylase variant, rs62445903, also associated with retroactive interference (P = 7.21 × 10−7, β = 0.3). These data suggest a role for dopaminergic genes, specifically a gene involved in regulation of dopamine synthesis, in cognitive performance in type 2 diabetes.


  • Analysis of coding variants identified from exome sequencing resources for association with diabetic and non-diabetic nephropathy in African Americans

    by Jessica N. Cooke Bailey, Nicholette D. Palmer, Maggie C. Y. Ng, Jason A. Bonomo, Pamela J. Hicks, Jessica M. Hester, Carl D. Langefeld, Barry I. Freedman, Donald W. Bowden

    Prior studies have identified common genetic variants influencing diabetic and non-diabetic nephropathy, diseases which disproportionately affect African Americans. Recently, exome sequencing techniques have facilitated identification of coding variants on a genome-wide basis in large samples. Exonic variants in known or suspected end-stage kidney disease (ESKD) or nephropathy genes can be tested for their ability to identify association either singly or in combination with known associated common variants. Coding variants in genes with prior evidence for association with ESKD or nephropathy were identified in the NHLBI-ESP GO database and genotyped in 5,045 African Americans (3,324 cases with type 2 diabetes associated nephropathy [T2D-ESKD] or non-T2D ESKD, and 1,721 controls) and 1,465 European Americans (568 T2D-ESKD cases and 897 controls). Logistic regression analyses were performed to assess association, with admixture and APOL1 risk status incorporated as covariates. Ten of 31 SNPs were associated in African Americans; four replicated in European Americans. In African Americans, SNPs in OR2L8, OR2AK2, C6orf167 (MMS22L), LIMK2, APOL3, APOL2, and APOL1 were nominally associated (P = 1.8 × 10−4–0.044). Haplotype analysis of common and coding variants increased evidence of association at the OR2L13 and APOL1 loci (P = 6.2 × 10−5 and 4.6 × 10−5, respectively). SNPs replicating in European Americans were in OR2AK2, LIMK2, and APOL2 (P = 0.0010-0.037). Meta-analyses highlighted four SNPs associated in T2D-ESKD and all-cause ESKD. Results from this study suggest a role for coding variants in the development of diabetic, non-diabetic, and/or all-cause ESKD in African Americans and/or European Americans.


  • Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics

    by Jacklyn N. Hellwege, Nicholette D. Palmer, Julie T. Ziegler, Carl D. Langefeld, Carlos Lorenzo, Jill M. Norris, Toshinari Takamura, Donald W. Bowden


  • Estimating the Contributions of Rare and Common Genetic Variations and Clinical Measures to a Model Trait: Adiponectin

    by S. Sandy An, Nicholette D. Palmer, Anthony J. G. Hanley, Julie T. Ziegler, W. Mark Brown, Steven M. Haffner, Jill M. Norris, Jerome I. Rotter, Xiuqing Guo, Y.‐D. Ida Chen, et al.

    Common genetic variation frequently accounts for only a modest amount of interindividual variation in quantitative traits and complex disease susceptibility. Circulating adiponectin, an adipocytokine implicated in metabolic disease, is a model for assessing the contribution of genetic and clinical factors to quantitative trait variation. The adiponectin locus, ADIPOQ , is the primary source of genetically mediated variation in plasma adiponectin levels. This study sought to define the genetic architecture of ADIPOQ in the comprehensively phenotyped Hispanic (n = 1,151) and A frican A merican (n = 574) participants from the Insulin Resistance Atherosclerosis Family Study (IRASFS ). Through resequencing and bioinformatic analysis, rare/low frequency (5% MAF ) in ADIPOQ were identified. Genetic variants and clinical variables were assessed for association with adiponectin levels and contribution to adiponectin variance in the H ispanic and A frican American cohorts. Clinical traits accounted for the greatest proportion of variance (POV ) at 31% (P = 1.16 × 10−47) and 47% (P = 5.82 × 10−20), respectively. Rare/low frequency variants contributed more than common variants to variance in H ispanics: POV = 18% (P = 6.40 × 10−15) and POV = 5% (P = 0.19), respectively. In A frican A mericans, rare/low frequency and common variants both contributed approximately equally to variance: POV = 6% (P = 5.44 × 10−12) and POV = 9% (P = 1.44 × 10−10), respectively. Importantly, single low frequency alleles in each ethnic group were as important as, or more important than, common variants in explaining variation in adiponectin. Cumulatively, these clinical and ethnicity‐specific genetic contributors explained half or more of the variance in H ispanic and A frican A mericans and provide new insight into the sources of variation for this important adipocytokine.


  • Relevance of the ACTN4 Gene in African-Americans with Non-Diabetic End-Stage Renal Disease

    by Meredith A. Bostrom, Peter Perlegas, Lingyi Lu, Pamela J. Hicks, Greg Hawkins, Maggie C.Y. Ng, Carl D. Langefeld, Barry I. Freedman, Donald W. Bowden

    Background: African-Americans (AAs) are predisposed to non-diabetic (non-DM) end-stage renal disease (ESRD), and studies have shown a genetic component to this risk. Rare mutations in ACTN4 (α-actinin-4), an actin-binding protein expressed in podocytes, cause familial focal segmental glomerulosclerosis. Methods: We assessed the contribution of coding variants in ACTN4 to non-DM ESRD risk in AAs. Nineteen exons, 2,800 bases of the promoter and 392 bases of the 3′ untranslated region of ACTN4 were sequenced in 96 AA non-DM ESRD cases and 96 non-nephropathy controls (384 chromosomes). Sixty-seven single-nucleotide polymorphisms (SNPs) including 51 novel SNPs were identified. The SNPs comprised 33 intronic, 21 promoter, 12 exonic, and one 3′ variant. Sixty-two of the SNPs were genotyped in 296 AA non-DM ESRD cases and 358 non-nephropathy controls. Results: One SNP, rs10404257, was associated with non-DM ESRD (p < 1.0E–4, odds ratio, OR = 0.76; confidence interval, CI = 0.59–0.98; additive model). Forty-seven SNPs had minor allele frequencies APOL1 gene, previously associated with non-DM ESRD in AAs, and rs10404257 was modestly associated (p = 0.0261, additive model). Conclusions: This detailed evaluation of ACTN4 variation revealed limited evidence of association with non-DM ESRD in AAs.


  • Open Access

    The Challenging Search for Diabetic Nephropathy Genes

    by Donald W. Bowden, Barry I. Freedman


  • Open Access

    Genetic Risk Assessment of Type 2 Diabetes–Associated Polymorphisms in African Americans

    by Jessica N. Cooke, Maggie C.Y. Ng, Nicholette D. Palmer, S. Sandy An, Jessica M. Hester, Barry I. Freedman, Carl D. Langefeld, Donald W. Bowden

    OBJECTIVE: Multiple single nucleotide polymorphisms (SNPs) associated with type 2 diabetes (T2D) susceptibility have been identified in predominantly European-derived populations. These SNPs have not been extensively investigated for individual and cumulative effects on T2D risk in African Americans. RESEARCH DESIGN AND METHODS: Seventeen index T2D risk variants were genotyped in 2,652 African American case subjects with T2D and 1,393 nondiabetic control subjects. Individual SNPs and cumulative risk allele loads were assessed for association with risk for T2D. Cumulative risk was assessed by counting risk alleles and evaluating the difference in cumulative risk scores between case subjects and control subjects. A second analysis weighted risk scores (ln [OR]) based on previously reported European-derived effect sizes. RESULTS: Frequencies of risk alleles ranged from 8.6 to 99.9%. Eleven SNPs had ORs >1, and 5 from ADAMTS9, WFS1, CDKAL1, JAZF1, and TCF7L2 trended or had nominally significant evidence of T2D association (P < 0.05). Individuals carried between 13 and 29 risk alleles. Association was observed between T2D and increase in risk allele load (unweighted OR 1.04 [95% CI 1.01–1.08], P = 0.010; weighted 1.06 [1.03–1.10], P = 8.10 × 10−5). When TCF7L2 SNP rs7903146 was included as a covariate, the risk score was no longer associated with T2D in either model (unweighted 1.02 [0.98–1.05], P = 0.33; weighted 1.02 [0.98–1.06], P = 0.40). CONCLUSIONS: The trend of increase in risk for T2D with increasing risk allele load is similar to observations in European-derived populations; however, these analyses indicate that T2D genetic risk is primarily mediated through the effect of TCF7L2 in African Americans.


  • Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans

    by J. N. Cooke, M. A. Bostrom, P. J. Hicks, M. C. Y. Ng, J. N. Hellwege, M. E. Comeau, J. Divers, C. D. Langefeld, B. I. Freedman, D. W. Bowden

    Polymorphisms in the non-muscle myosin IIA gene (MYH9) are associated with focal segmental glomerulosclerosis (FSGS) and non-diabetic end-stage renal disease (ESRD) in African Americans and FSGS in European Americans. We tested for association of single nucleotide polymorphisms (SNPs) in MYH9 with T2DM-ESRD in European Americans; additionally, three APOL1 gene variants were evaluated. Fifteen MYH9 SNPs and two APOL1 SNPs plus a 6-bp deletion were genotyped in 1963 European Americans, 536 cases with T2DM-ESRD and 1427 non-nephropathy controls (467 with T2DM and 960 without diabetes). Comparing T2DM-ESRD cases with the 467 T2DM non-nephropathy controls, single variant associations trending toward significance were detected with SNPs rs4821480, rs2032487 and rs4281481 comprising part of the major MYH9 E1 risk haplotype [P-values 0.053-0.055 recessive, odds ratio (OR) 6.08-6.14]. Comparing T2DM-ESRD cases to all 1427 non-nephropathy controls, we confirmed evidence of association in these three SNPs as well as in the fourth E1 SNP (rs3752462) (P-values 0.017-0.035, OR 1.41-3.72). APOL1 G1/G2 nephropathy risk variants were rare in individuals of European American heritage, present in 0.28% of chromosomes in T2DM-ESRD cases and 0.32% of controls. MYH9 SNPs rs4821480, rs2032487, rs4281481 and rs3752462 are associated with T2DM-ESRD susceptibility in European Americans. The APOL1 risk variants are not present at appreciable frequency in this cohort with T2DM-ESRD. Therefore, polymorphisms in MYH9 appear to influence nephropathy risk in this sample.